Page last updated: 2024-08-23

lovastatin and Lymphoma, Primary Effusion

lovastatin has been researched along with Lymphoma, Primary Effusion in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cirone, M; D'Orazi, G; Gilardini Montani, MS; Gonnella, R; Pompili, C; Romeo, MA; Santarelli, R1

Other Studies

1 other study(ies) available for lovastatin and Lymphoma, Primary Effusion

ArticleYear
Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.
    IUBMB life, 2021, Volume: 73, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Humans; Lovastatin; Lymphoma, Primary Effusion; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrosine

2021